HIV-Infected patients
Because TB therapy is complicated by co-infection with HIV, testing for HIV infection is recommended for all patients with active tuberculosis. To minimize the risk of resistance, treatment in the continuation phase should be given once daily or three times weekly. Twice weekly regimens should not be given to patients with CD4 cell counts <100 cells/mm3 because they have been associated with rifamycin resistance. Rifapentine is not recommended for TB treatment in HIV-infected patients because it has been associated with development of rifamycin resistance.